A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity

International Journal of Obesity

Volumn 24, Issue 2, 2000, Pages 144-150

  Fanghanel G ^a   Cortinas, L ^a   Sanchez Reyes L ^a   Berber, A ^b  

^a Organo Descentralizado   (Mexico)

^b BASF Mexicana SA de CV   (Mexico)

Author keywords

Clinical trial; Double blind; Obesity treatment; Placebo controlled; Sibutramine

Indexed keywords

ANTIDEPRESSANT AGENT; SIBUTRAMINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY SIZE; BODY WEIGHT; CLINICAL TRIAL; CONSTIPATION; DIET; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HUMAN; HUNGER; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SATIETY; TACHYCARDIA; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0033974882     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801098     Document Type: Article

References (22)

1. 1 World Health Organisation. Report of WHO study group: Diet, nutrition and the prevention of chronic diseases. Technical Report Service 797. WHO: Geneva, 1990.
2. 2 Kuczmarski RJ, Carrol MD, Flegal KM, Troiano RP. Varying body mass index cut-off points to describe overweight prevalence among U.S. adults: NHANES III (1988 to 1994). Obes Res 1997; 5: 542-548.
3. 3 World Health Organisation. Obesity epidemic puts millions at risk from related diseases. Press Release WHO/46, 12 June 1997.
4. 4 Pi-Sunyer FX. Medical Hazards of obesity. Ann Intern Med 1993; 119: 655-660.
5. 5 Colditz GA, Willet WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501-513.
6. 6 Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67: 968-977.
7. 7 Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, Speizer FE, Manson JE. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997; 277: 1539-1545.
8. 8 Pi-sunyer XA. A review of long-term studies evaluating the efficacy of weight loss in ameliorting disorders associated with obesity. Clin Ther 1996; 18: 1006 -1036.
9. 9 Stern JS, Hirsch J, Blair SN, Foreyt JP, Frank A, Kumanyika SK, Madans JH, Marlatt GA, St Jeor ST, Stunkard AJ. Weighing the options: Criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995; 3: 591-604.
10. 10 DePue JD, Clark MM, Ruggiero L, Medeiros ML, Pera V Jr. Maintenace of weight loss: A needs assessment. Obes Res 1995; 3: 241-248.
11. 11 Expert panel on the Identification, Evaluation and Treatment of overweight in Adults. Pi Sunyer FX, Becker DM, Bouchard C, Carleton RA, Colditz GA, Dietz WH, Foreyt JP, Garrison RJ, Grundy SM, Hansen BC, Higgins M, Hill JO, Howard BV, Kuczmarski RJ, Kumanyika S, Legako RD, Prewitt TE, Rocchini AP, Smith PL, Snetselaar LG, Sowers JR, Weintraub M, Williamson DF, Wilson GT, Brown CD, Donato KA, Ernst N, Hill DR, Horan MJ, Hubbard VS, Kiley JP, Obarzanek E, Schriger D, Chiquettc E. Clinical guidelines on the identifica-tion, evaluation, and treatment of overweight and obesity in adults: Executive summary. Am J Clin Nutr 1998; 68: 899-971.
12. 12 National Task Force on the Prevention and Treatment of Obesity. Long-term Pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-1915.
13. 13 Stock MJ. Sibutramine: A review of the pharmacology of a novel anti-obesity agent. Int J Obes 1997; 21(Suppl 1): S25-S29.
14. 14 Cole JO, Levin A, Beake B, Kaiser PE, Schienbaum ML. Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. J Clin Psycopharmac 1998; 18: 231-236.
15. 15 Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of Sibutramine in humans. Am J Clin Nutr 1998; 68; 1180-1186.
16. 16 Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in eight control: a dose-ranging efficacy study. Clin Pharmac Ther 1991; 50: 330-337.
17. 17 Bray GA, Ryan DH, Gordon D, Heidingfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of Sibutramine. Obes Res 1996; 4: 263-270.
18. 18 Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of Sibutraminc in obese patients: A dose-ranging study. Int J Obes Relat Metab Disord 1998; 22: 32-38.
19. 19 Glantz SA. What does 'not significant' really mean? In Primer of biostatistics, 3rd edn, Chap 6. McGraw-Hill: New York, 1992, pp 155-187.
20. 20 Williamson DF. Pharmeotherapy for obesity. JAMA 1999; 281: 278-280 (editorial).
21. 21 Norusis MJ. Multiple linear regression analysis. In SPSS for Windows based system, user's guide, Relese 6.0. SPSS: Chicago, 11, 1993; pp 311-376.
22. 22 Lean MEJ. Sibutramine-a review of clinical efficacy. Int J Obes 1997; 21(Suppl 1): S30-S35.